Does Rallies show 13F holders for FATE?

Yes. Rallies tracks hedge fund and 13F ownership data for FATE, including fund names, share counts, latest tracked quarter, and position changes when available.

Is FATE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for FATE. It does not provide personalized investment advice.

FATE (Fate Therapeutics, Inc.) Stock Analysis - Hedge Fund Holdings

Fate Therapeutics, Inc. (FATE) is a publicly traded Healthcare sector company. As of May 20, 2026, FATE trades at $1.93 with a market cap of $201.65M and a P/E ratio of -1.69. FATE moved +1.85% today. Year to date, FATE is +91.61%; over the trailing twelve months it is +54.92%. Its 52-week range spans $0.66 to $3.80. Analyst consensus is buy with an average price target of $4.46. Rallies surfaces FATE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns FATE stock?

Hedge funds tracked by Rallies that own FATE include Redmile Group, Orbimed Advisors, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Fate Therapeutics, Inc..

FATE Key Metrics

Key financial metrics for FATE
Metric	Value
Price	$1.93
Market Cap	$201.65M
P/E Ratio	-1.69
EPS	$-1.09
Dividend Yield	0.00%
52-Week High	$3.80
52-Week Low	$0.66
Volume	1.46M
Avg Volume	0
Revenue (TTM)	$6.32M
Net Income	$-129.91M
Gross Margin	0.00%

Top Hedge Funds Holding FATE

Redmile Group holds 12.87M shares of FATE, changed +0.00% as of Mar 31, 2026.
Orbimed Advisors holds 1.68M shares of FATE, changed +0.00% as of Mar 31, 2025.
Panagora Asset holds 356.74K shares of FATE, changed +0.00% as of Dec 31, 2023.

Latest FATE News

Cell Therapy Market to Exceed $20 B by 2030, Boosting Fate Therapeutics — May 20, 2026
Fate Therapeutics Beats Q1 EPS, Misses Revenue Estimate, Extends Runway to 2028 — May 13, 2026
Fate Therapeutics to Dose 900M Cells in 53-Patient Phase 2 Lupus Trial — May 13, 2026
Fate Therapeutics Treats 19 Autoimmune Patients Outpatient with FT819 CAR T — Mar 27, 2026
Fate Therapeutics Posts Q4 Loss of $0.27, Revenue Drops 26% to $1.37M — Feb 26, 2026

Recent FATE Insider Trades

TAHL CINDY sold 10.59K (~$11.28K) on Jan 9, 2026.
Valamehr Bahram sold 5.19K (~$5.56K) on Jan 9, 2026.
TAHL CINDY sold 9.04K (~$9.57K) on Aug 4, 2025.

FATE Analyst Consensus

7 analysts cover FATE: 0 strong buy, 3 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.46.

Common questions about FATE

Who owns FATE stock?: Hedge funds tracked by Rallies that own FATE include Redmile Group, Orbimed Advisors, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Fate Therapeutics, Inc..
Does Rallies show 13F holders for FATE?: Yes. Rallies tracks hedge fund and 13F ownership data for FATE, including fund names, share counts, latest tracked quarter, and position changes when available.
Is FATE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for FATE. It does not provide personalized investment advice.